Drug Profile
Research programme: virus-like particle vaccines - VBI Vaccines
Alternative Names: CMV eVLP - VBI; eVLP vaccines - VBI; HCV eVLP - VBI; Prophylactic respiratory syncytial virus vaccine - VBI Vaccines; RSV vaccine - VBI Vaccines; VLP-based Cytomegalovirus - VBILatest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator VBI Vaccines
- Class Antineoplastics; Cancer vaccines; Viral vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer; Cytomegalovirus infections
- No development reported Hepatitis C; Respiratory syncytial virus infections
Most Recent Events
- 28 Jan 2022 Preclinical development in Cytomegalovirus infections (Prevention) is ongoing in Canada (VBI Vaccines pipeline, January 2022)
- 28 Jan 2022 Virus-like particle vaccines - VBI Vaccines is available for licensing as of 28 Jan 2022. https://www.vbivaccines.com/
- 01 Jan 2022 Preclinical trials in Cancer in Canada (Parenteral) before January 2022 (VBI Vaccines pipeline, January 2022)